Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer
- 285 Downloads
Purpose: We report the first phase I trials of 2-methoxyestradiol (2ME2, Panzem® Capsules, EntreMed, Rockville, MD), alone and in combination with docetaxel, in patients with metastatic breast cancer (MBC).
Patients and methods: In Trial 001, 2ME2 monotherapy was administered orally once (200–1000 mg/d, cohorts 1–5) or twice daily (200–800 mg/q12h, cohorts 6–9) for 28 days followed by a 14-day observation period, continuously thereafter. In Trial 002, docetaxel 35 mg/m2 was administered weekly for four of six weeks for a maximum six cycles; 2ME2 (200–1000 mg/d) was given orally once daily for 28 days followed by a 13-day observation period in cycle one, continuously thereafter. In both trials, responding or stable patients continued 2ME2 until progression.
Results: Trial 001 enrolled 31 patients; there were no objective responses. Trial 002 enrolled 15 patients; ORR was 20% including one CR. There were no Grade IV toxicities; MTD was not reached in either study. When combined with docetaxel, three patients had significant transaminase elevations that returned to normal with continued treatment (in two of three patients). There was significant inter-patient variability and extensive metabolism to 2-methoxyestrone (2ME1). Steady-state AUC and trough concentrations of 2ME2 increased linearly up to 400–600 mg/d; doses above 400–600 mg/d did not increase 2ME2 levels. The target trough concentration (3–25 ng/mL) was not attained. Combined administration did not alter docetaxel or 2ME2 pharmacokinetics.
Conclusion: 2ME2, alone or in combination with docetaxel, was well tolerated in patients with MBC but systemic exposure remained below the expected therapeutic range.
KeywordsAngiogenesis Breast cancer Clinical trial
Supported by the American Cancer Society grant # CRTG-00-199-01-CCE (KDM) a Career Development Award from the American Society of Clinical Oncology (KDM), Breast Cancer Research Foundation (GWS, KDM) and research supported by EntreMed, Inc.
- 2.Gasparini G (1999) Angiogenesis in breast cancer. Role in biology, tumor progression, and prognosis. In: Bowcock A (ed) Breast cancer: Molecular Genetics, Pathogenesis, and Therapeutics. Humana Press Inc, Totowa, NJ, pp 347–371Google Scholar
- 20.Yue T-L, Wang X, Louden C et al (1997) 2-methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and fas activation. Molecular Pharmacol 51:951–962Google Scholar
- 21.Sweeney CJ, Miller KD, Sissons SE et al (2001) The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-Methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369–3372PubMedGoogle Scholar
- 26.Sweeney C, Liu G, Yiannoutsos C et al (2005) A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 11:6625–6633PubMedCrossRefGoogle Scholar
- 28.Miller KD, Trigo JM, Wheeler C et al (2005) A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 11:3369–3376PubMedCrossRefGoogle Scholar
- 29.Loeffler T, Droege C, Hausamen T et al (1999) Dose-dense weekly docetaxel in metastatic breast cancer. Breast Cancer Res Treat 57:125Google Scholar
- 31.Fornasiero A, Danilel O, Ghiotto C et al (1999) Weekly docetaxel for metastatic breast cancer: A phase II trial. Breast Cancer Res Treat 57:127Google Scholar
- 32.Kim Y, Takatsuka Y, Tanigawara Y et al (2000) Weekly docetaxel for patients with recurrent breast cancer: clinical results and pharmacokinetic/pharmacodynamic assessment. Proc Am Soc Clin Oncol 19:113aGoogle Scholar
- 33.Mey U, Kleinschmidt R, Sauerbruch T et al (1999) A phase II trial of weekly docetaxel in patients with advanced metastatic breast cancer - preliminary results. Proc Am Soc Clin Oncol 18:134aGoogle Scholar
- 34.Miranda F, Burris H, Greco F et al (1999) Phase II trial of weekly docetaxel in the treatment of patients who are elderly or medically compromised: A Minnie Pearl Research Network Study. Proc Am Soc Clin Oncol 18:601aGoogle Scholar
- 35.Rittershaus A, Luck H, Scholz U et al (1999) Weekly docetaxel in pretreated patients with metastatic breast cancer. Breast Cancer Res Treat 57:126Google Scholar